Hvivo (HVO) , led by CEO Mo Khan, has signed a $2.5 million contract to conduct a characterization study on the Omicron variant of COVID-19. This study aims to determine the minimum dose of the virus required to cause a measurable infection in vaccinated individuals, which will then facilitate human challenge trials to test the efficacy of vaccines and antivirals.
Mr Khan explained that this study is a precursor to more extensive human challenge trials. If successful, it could lead to multiple trials in 2025 and 2026, expanding hVIVO’s market opportunities. The study will commence later this year, with significant developments expected in 2025.
hVIVO previously conducted the world’s first COVID-19 human challenge trial, setting a precedent for safely and effectively managing such studies during a pandemic. This earlier trial involved the original COVID-19 strain and unvaccinated volunteers, whereas the new study will involve healthy, vaccinated participants and utilize Hvivo’s new in-house facilities. The company has invested in a state-of-the-art quarantine and laboratory facility capable of processing and analyzing COVID-19 samples.
The recruitment of volunteers, a critical aspect of such trials, will leverage hVIVO’s existing infrastructure, including a 300,000-strong volunteer database and advanced CRM systems. The company’s adept use of social media platforms like TikTok and Instagram has enhanced its recruitment efficiency.
Despite the pandemic's official end, COVID-19 remains prevalent, with significant infection rates. New vaccine developments, including mucosal and multivalent vaccines, are underway to improve upon the limitations of initial vaccines, such as their inability to prevent transmission. These advancements highlight the ongoing need for COVID-19 research and trials.
Mr Khan emphasized the importance of this contract in maintaining pandemic preparedness and advancing next-generation vaccine development. hVIVO’s strategic investments and timely execution have positioned the company to play a crucial role in future COVID-19 research and trials.